Company intelligence / Profile preview

Replimune Group, Inc.

Woburn, Massachusetts, United Statesx.com ↗

Ownership: Public · REPL
Employees: ~331
Development stage: Phase 2

Overview

Replimune has a Biologics License Application under priority review for RP1 for the treatment of advanced melanoma. The company has multiple ongoing clinical programs evaluating their therapies in various solid tumor cancers, both as single agents and in combination with other immunotherapies.

Therapeutic areas: Oncology
Modalities: Oncolytic immunotherapiesOncolytic viruses
Industry: Biotech

Drug pipeline

7 assets

vusolimogene oderparepvec

Approved

6 more assets in the full pipeline.

Request access →

Financials

Market cap: $1.2B
Total revenue: $0
Enterprise value: $1.2B

Beyond the preview

Go deeper on Replimune Group, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Replimune Group, Inc..

Explore the full profile